Revised. Amendments from Version 1
==================================

In this updated version an additional table (Table 9)  has been added with an overview of the different administration routes of DMSO used in the included studies.

Introduction
============

The first medical report on the use of dimethyl sulfoxide (DMSO) as a pharmacological agent was published in 1964 ^[@ref-1]^. A year later, the use of DMSO in humans was terminated because experimental studies had shown refractive index changes to the lens of the eye ^[@ref-1],\ [@ref-2]^. Years later, DMSO was again approved for use in humans since this side effect was only proven in animal studies ^[@ref-2]^. DMSO has since been used for a variety of purposes, such as treatment of musculoskeletal and dermatological diseases, cryopreservation of stem cells, treatment of interstitial cystitis, treatment of increased intracranial pressure, and many more ^[@ref-3]--\ [@ref-9]^.

DMSO is a colourless liquid, which is rapidly absorbed when administered dermally or orally ^[@ref-10],\ [@ref-11]^. DMSO is used as a cryoprotectant because it decreases osmotic stress and cellular dehydration, and thereby enables stem cells to be stored for several years ^[@ref-12]^. DMSO is mostly excreted through the kidneys, but a small part is excreted through the lungs and liver ^[@ref-10]^. Part of the DMSO is transformed to the volatile metabolite dimethyl sulfide, which gives a characteristic garlic- or oyster-like smell when excreted through the lungs ^[@ref-10]^. DMSO may induce histamine release, which can be the reason for adverse reactions such as flushing, dyspnoea, abdominal cramps, and cardiovascular reactions ^[@ref-11]^.

To our knowledge, no systematic reviews have been performed on the adverse reactions of DMSO. Our aim was therefore to provide an extensive overview of the suspected adverse reactions to DMSO in humans.

Methods
=======

Protocol and eligibility criteria
---------------------------------

Our study-protocol is registered at PROSPERO (Registration number: [CRD42018096117](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=96117)). The systematic review was performed according to PRISMA-harms (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines ^[@ref-13]^.

No limitations were set on the date of publication. The language was restricted to English, Danish, Swedish, Norwegian, and Russian. We included all original studies that administered DMSO to humans and included five or more participants. There was no gender or age restriction. For a study to be included, the authors had to suspect that an observed adverse reaction could be caused by DMSO.

Primary outcome
---------------

The primary outcome was any adverse reaction seen in relation to the use of DMSO in humans.

Literature search
-----------------

The search was performed in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/) (1966-present), [EMBASE](https://www.elsevier.com/solutions/embase-biomedical-research) (1980-present), and the [Cochrane Library](https://www.cochranelibrary.com/). The databases were last searched on February 23, 2018. Our search strategy was formulated with the help of a medical research librarian.

The search string used in PubMed was: ((dimethyl sulfoxide) OR DMSO) AND ((((((administration and dosage) OR adverse reactions) OR alternate effects) OR secondary response) OR toxicology) OR side effects)). The search was restricted to humans. The search string was adapted to EMBASE and Cochrane Library using the same search-words as abovementioned.

The search string used in EMBASE was: ((dmso or dimethyl sulfoxide) and ((side effect or toxicology or secondary response or alternate effects or alternate reactions or (administration and dosage)) and (dmso or dimethyl sulfoxide))).mp. The search was restricted to humans, articles and Medline journals were excluded.

The search string used in Cochrane was: (adverse drug events and dimethyl sulfoxide). The search was restricted to trials.

Study selection and data extraction
-----------------------------------

Two authors (B.K.M. and D.Z.) independently screened title and abstract according to the eligibility criteria using [www.covidence.org](https://www.covidence.org). Discrepancies were resolved by discussion. One author screened the full-text articles (B.K.M.). Russian articles were screened by an author fluent in Russian (M.H.). If M.H. was in doubt regarding inclusion of a study the results were presented to B.K.M. and then discussed until a mutual decision was made.

After the screening process was finished, all included studies were imported to an Excel sheet (Microsoft Excel 2016). Data extraction was performed by two authors (M.H. extracted from the Russian articles and B.K.M. extracted from the rest). Data extracted were: author, publication year, country, study characteristics (study design, sample size, size of comparison group if present, time to follow-up), use of DMSO (reason for use, treatment duration, administration route, dose of DMSO), and adverse reactions observed (number of persons experiencing an adverse reaction, method of assessing, and duration of adverse reaction).

Analysis
--------

The Newcastle-Ottawa-Scale was used to assess the risk of bias in non-randomized observational studies ^[@ref-14]^. Risk of bias in randomized controlled trials was assessed using the Cochrane Handbook "Risk of Bias" assessment tool ^[@ref-15]^. Risk of bias was assessed at the outcome level.

The primary summary measure was percentage of persons experiencing an adverse reaction, as well as the range in which a reaction occurred in the studies included. No meta-analysis and further summery measures were planned due to the expected large heterogeneity of the studies.

Results
=======

Study selection
---------------

Our primary search identified 2599 studies ( [Figure 1](#f1){ref-type="fig"}). After the evaluation process, 109 studies were included in the final review ^[@ref-2],\ [@ref-4],\ [@ref-6]--\ [@ref-9],\ [@ref-16]--\ [@ref-118]^.

![PRISMA flow diagram.](f1000research-7-22126-g0000){#f1}

Gastrointestinal reactions
--------------------------

Gastrointestinal adverse reactions were reported in 61 studies. Of these, 10 studies were randomized controlled trials ^[@ref-16],\ [@ref-30],\ [@ref-33],\ [@ref-55],\ [@ref-57],\ [@ref-59],\ [@ref-67],\ [@ref-79],\ [@ref-93],\ [@ref-95]^, 49 were cohort studies ^[@ref-2],\ [@ref-4],\ [@ref-7],\ [@ref-9],\ [@ref-18],\ [@ref-19],\ [@ref-23],\ [@ref-25]--\ [@ref-27],\ [@ref-29],\ [@ref-35],\ [@ref-38]--\ [@ref-43],\ [@ref-45],\ [@ref-46],\ [@ref-48],\ [@ref-50]--\ [@ref-54],\ [@ref-58],\ [@ref-60],\ [@ref-66],\ [@ref-68],\ [@ref-69],\ [@ref-71],\ [@ref-73],\ [@ref-83],\ [@ref-85]--\ [@ref-88],\ [@ref-90],\ [@ref-94],\ [@ref-97],\ [@ref-98],\ [@ref-101],\ [@ref-104],\ [@ref-105],\ [@ref-112],\ [@ref-113],\ [@ref-115],\ [@ref-118]^, and 2 were case series ^[@ref-84],\ [@ref-109]^. Most studies reported the number of patients experiencing an adverse reaction ( [Table 1](#T1){ref-type="table"}). Other studies reported adverse reactions observed in relation to the number of treatments given ( [Table 2](#T2){ref-type="table"}).

###### Gastrointestinal adverse reactions observed per number of patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse reaction                                      Studies                                                                                                                                                                                                               Total\        Patients\         (%, min-max) [†](#fn2){ref-type="other"}
                                                                                                                                                                                                                                                                              patients, n   with adverse\     
                                                                                                                                                                                                                                                                                            reaction, n (%)   
  ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ----------------- ------------------------------------------------------------
  **Nausea** *(overall incidence)*                      \[ [@ref-2], [@ref-18], [@ref-27], [@ref-33], [@ref-45], [@ref-46], [@ref-48], [@ref-53], [@ref-55], [@ref-57], [@ref-59], [@ref-60], [@ref-67], [@ref-84], [@ref-90], [@ref-93], [@ref-109], [@ref-118]\]            2214          257 (12)          (2--41) \[ [@ref-55]\] - \[ [@ref-48]\]

    Intravenous administration                          \[ [@ref-18], [@ref-27], [@ref-33], [@ref-46], [@ref-48], [@ref-53], [@ref-59], [@ref-90], [@ref-118]\]                                                                                                               1154          199 (17)          (2--41) \[ [@ref-59]\] - \[ [@ref-48]\]

    Transdermal application                             \[ [@ref-2], [@ref-45], [@ref-55], [@ref-57], [@ref-67], [@ref-93], [@ref-109]\]                                                                                                                                      1039          51 (5)            (2--32) \[ [@ref-55]\] - \[ [@ref-2]\]

    \>1 administration route                            \[ [@ref-60], [@ref-84]\]                                                                                                                                                                                             21            7 (33)            (29--36) \[ [@ref-84]\] - \[ [@ref-60]\]

  **Vomiting** *(overall incidence)*                    \[ [@ref-2], [@ref-18], [@ref-27], [@ref-33], [@ref-46], [@ref-48], [@ref-55], [@ref-57], [@ref-59], [@ref-118]\]                                                                                                     1611          115 (7)           (0--64) \[ [@ref-55]\] - \[ [@ref-48]\]

    Intravenous administration                          \[ [@ref-18], [@ref-27], [@ref-33], [@ref-46], [@ref-48], [@ref-59], [@ref-118]\]                                                                                                                                     972           108 (11)          (2--64) \[ [@ref-59]\] - \[ [@ref-48]\]

    Transdermal application                             \[ [@ref-2], [@ref-55], [@ref-57]\]                                                                                                                                                                                   639           7 (1)             (0--6) \[ [@ref-55]\] - \[ [@ref-2]\]

  **Nausea and vomiting** [‡](#fn3){ref-type="other"}   \[ [@ref-7], [@ref-38], [@ref-41], [@ref-54], [@ref-66], [@ref-69], [@ref-73], [@ref-85], [@ref-87], [@ref-115]\]                                                                                                     4529          591 (13)          (0--46) \[ [@ref-66]\] - \[ [@ref-73]\]

  **Abdominal cramps/stomach**\                         \[ [@ref-18], [@ref-26], [@ref-27], [@ref-39], [@ref-41], [@ref-54], [@ref-55], [@ref-59], [@ref-73], [@ref-85], [@ref-87], [@ref-93], [@ref-115]\]                                                                   1629          88 (5)            (1--52) \[ [@ref-117]\] - \[ [@ref-116]\]
  **ache** *(overall incidence)*                                                                                                                                                                                                                                                                              

    Intravenous administration                          \[ [@ref-18], [@ref-26], [@ref-27], [@ref-39], [@ref-41], [@ref-54], [@ref-59], [@ref-73], [@ref-85], [@ref-87], [@ref-115]\]                                                                                         1253          72 (6)            (1--52) \[ [@ref-18]\] - \[ [@ref-26]\]

    Transdermal application                             \[ [@ref-55], [@ref-93]\]                                                                                                                                                                                             376           16 (4)            (2--16) \[ [@ref-55]\] - \[ [@ref-93]\]

  **Halitosis/garlic-like breath**\                     \[ [@ref-4], [@ref-9], [@ref-16], [@ref-19], [@ref-29], [@ref-30], [@ref-35], [@ref-42], [@ref-43], [@ref-45], [@ref-50], [@ref-52], [@ref-55], [@ref-57], [@ref-58], [@ref-66]-- [@ref-68], [@ref-79], [@ref-83],\   5782          607 (11)          (0--100) \[ [@ref-30]\] -\
  *(overall incidence)*                                 [@ref-85], [@ref-88], [@ref-94], [@ref-95], [@ref-97], [@ref-98], [@ref-109], [@ref-112], [@ref-113]\]                                                                                                                                                \[ [@ref-19], [@ref-43], [@ref-45], [@ref-83], [@ref-98]\]

    Intravenous administration                          \[ [@ref-16], [@ref-85], [@ref-94], [@ref-98]\]                                                                                                                                                                       239           14 (6)            (1--100) \[ [@ref-85]\] - \[ [@ref-98]\]

    Transdermal application                             \[ [@ref-4], [@ref-19], [@ref-29], [@ref-30], [@ref-42], [@ref-45], [@ref-50], [@ref-52], [@ref-55], [@ref-57], [@ref-58], [@ref-66], [@ref-67], [@ref-79], [@ref-83], [@ref-88], [@ref-95], [@ref-109],\             5333          556 (10)          (0--100) \[ [@ref-30]\]\
                                                        [@ref-112], [@ref-113]\]                                                                                                                                                                                                                              - \[ [@ref-19], [@ref-45], [@ref-83]\]

    Intravesical administration                         \[ [@ref-35], [@ref-43], [@ref-97]\]                                                                                                                                                                                  165           33 (20)           (1--100) \[ [@ref-35]\] - \[ [@ref-43]\]

    Oral administration                                 \[ [@ref-9]\]                                                                                                                                                                                                         15            4 (27)            

  **Diarrhea** *(overall incidence)*                    \[ [@ref-2], [@ref-18], [@ref-41], [@ref-54], [@ref-57], [@ref-85], [@ref-93]\]                                                                                                                                       1107          27 (2)            (1--6) \[ [@ref-85]\] - \[ [@ref-93]\]

    Intravenous administration                          \[ [@ref-18], [@ref-41], [@ref-54], [@ref-85]\]                                                                                                                                                                       744           15 (2)            (1--6) \[ [@ref-85]\] - \[ [@ref-41]\]

    Transdermal application                             \[ [@ref-2], [@ref-57], [@ref-93]\]                                                                                                                                                                                   363           12 (3)            (2--6) \[ [@ref-57]\] - \[ [@ref-93]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Incidences of the adverse reactions have been calculated for all the individual studies. (min%--max%) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.

‡ Nausea and vomiting are reported as one combined adverse reaction in some studies.

###### Gastrointestinal adverse reactions observed per number of treatments.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse reaction                                                Studies                                                       Total\          Adverse reactions\   (min%--max%) [†](#fn4){ref-type="other"}
                                                                                                                                treatments, n   observed, n (%)      
  --------------------------------------------------------------- ------------------------------------------------------------- --------------- -------------------- -------------------------------------------
  **Nausea** *(overall incidence)*                                \[ [@ref-40], [@ref-51], [@ref-68], [@ref-84], [@ref-105]\]   474             161 (34)             (16--57) \[ [@ref-105]\] - \[ [@ref-40]\]

    Intravenous administration                                    \[ [@ref-40], [@ref-51], [@ref-68]\]                          323             137 (42)             (41--57) \[ [@ref-68]\] - \[ [@ref-40]\]

    Intravesical administration                                   \[ [@ref-105]\]                                               151             24 (16)              

  **Vomiting [‡](#fn5){ref-type="other"}**                        \[ [@ref-51], [@ref-68]\]                                     316             112 (35)             (29 - 71) \[ [@ref-68]\] - \[ [@ref-51]\]

  **Nausea and/or vomiting [‡](#fn5){ref-type="other"}**          \[ [@ref-25], [@ref-74], [@ref-101]\]                         1557            220 (14)             (8--17) \[ [@ref-25]\] - \[ [@ref-101]\]

  **Abdominal cramps/stomach ache [‡](#fn5){ref-type="other"}**   \[ [@ref-51], [@ref-68], [@ref-101]\]                         495             16 (5)               (1--19) \[ [@ref-68]\] - \[ [@ref-51]\]

  **Halitosis [‡](#fn5){ref-type="other"}**                       \[ [@ref-68]\]                                                262             4 (2)                

  **Diarrhea [‡](#fn5){ref-type="other"}**                        \[ [@ref-51], [@ref-101]\]                                    233             2 (1)                (1--2) \[ [@ref-101]\] - \[ [@ref-51]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^ Incidences of the adverse reactions have been calculated for all the individual studies. (min%--max%) are the lowest and highest observed incidence of an adverse reaction.

‡ Intravenous administration.

The most commonly reported gastrointestinal adverse reactions were nausea and vomiting. The incidence of nausea seems to be less common with the transdermal administration of DMSO compared with intravenous administration. The majority of studies reported an incidence of nausea between 2--14%, with the exception of one study, reporting an incidence of 32% ^[@ref-2]^. In one study that failed to specify the dose, 8 of 42 patients reported nausea and anorexia, but the symptoms disappeared in five of the eight patients when the dose of DMSO was reduced ^[@ref-45]^.

Often the studies had short follow-up periods (less than 24 hours), especially when DMSO was used as a cryoprotectant. The study reporting the highest incidence of nausea had a follow-up period of 5 days ^[@ref-48]^, and the authors concluded that the high incidence of nausea observed might be due to the long follow-up period ^[@ref-48]^. In another article using the same data ^[@ref-119]^, it was suggested that the delayed nausea was due to gastrointestinal mucosal damage, and only the initial nausea could be related to DMSO, and therefore we decided only to include the data from the first 2 days after infusion ^[@ref-48]^.

Halitosis was reported in 29 studies ^[@ref-4],\ [@ref-9],\ [@ref-16],\ [@ref-19],\ [@ref-29],\ [@ref-30],\ [@ref-35],\ [@ref-42],\ [@ref-43],\ [@ref-45],\ [@ref-50],\ [@ref-52],\ [@ref-55],\ [@ref-57],\ [@ref-58],\ [@ref-66]--\ [@ref-68],\ [@ref-79],\ [@ref-83],\ [@ref-85],\ [@ref-88],\ [@ref-94],\ [@ref-95],\ [@ref-97],\ [@ref-98],\ [@ref-109],\ [@ref-112],\ [@ref-113]^. In five studies, patients discontinued treatment due to halitosis ^[@ref-9],\ [@ref-45],\ [@ref-83],\ [@ref-94]^. In five studies, all patients experienced halitosis ^[@ref-9],\ [@ref-45],\ [@ref-83],\ [@ref-94]^. Unlike halitosis, other gastrointestinal side effects were reported more often when DMSO was administered intravenously, than transdermally or intravesically.

One study reported a severe case of nausea, vomiting, and abdominal cramps in one patient with an acute allergic reaction ^[@ref-59]^. However, in most studies the reported gastrointestinal reactions were transient and mild, often lasting only minutes to a couple of hours ^[@ref-16],\ [@ref-38],\ [@ref-41],\ [@ref-68],\ [@ref-85],\ [@ref-87],\ [@ref-90]^. Several studies reported a relationship between the dose of DMSO and the occurrence of gastrointestinal adverse reactions ^[@ref-26],\ [@ref-33],\ [@ref-53],\ [@ref-73],\ [@ref-83],\ [@ref-85]^.

Cardiovascular and respiratory reactions
----------------------------------------

Cardiovascular and respiratory adverse reactions were reported in 33 studies. Of these, two were randomized controlled trials ^[@ref-33],\ [@ref-59]^, 30 were cohort studies ^[@ref-7],\ [@ref-18],\ [@ref-23],\ [@ref-25]--\ [@ref-27],\ [@ref-36],\ [@ref-39]--\ [@ref-41],\ [@ref-51],\ [@ref-54],\ [@ref-61],\ [@ref-65],\ [@ref-66],\ [@ref-68],\ [@ref-73],\ [@ref-74],\ [@ref-80],\ [@ref-85]--\ [@ref-87],\ [@ref-90],\ [@ref-100]--\ [@ref-102],\ [@ref-104],\ [@ref-115],\ [@ref-117]^, and one was a preliminary report ^[@ref-91]^. Except for one study ^[@ref-66]^, all studies reporting cardiovascular and respiratory reactions administered DMSO intravenously ( [Table 3](#T3){ref-type="table"} and [Table 4](#T4){ref-type="table"}).

###### Cardiovascular and respiratory adverse reactions observed per number of patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse reaction                                                   Studies                                                                                                                        Total\        Patients with adverse\   (min%--max%) [†](#fn6){ref-type="other"}
                                                                                                                                                                                                    patients, n   reactions, n (%)         
  ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------ ------------- ------------------------ ----------------------------------------------------
  ***Cardiac***                                                                                                                                                                                                                            

     **Hypotension** [‡](#fn7){ref-type="other"}                     \[ [@ref-7], [@ref-18], [@ref-23], [@ref-33], [@ref-71], [@ref-73], [@ref-87], [@ref-104], [@ref-115]\]                        2752          115 (4)                  (1--14) \[ [@ref-18], [@ref-71]\] - \[ [@ref-87]\]

     **Hypertension** [§](#fn8){ref-type="other"}                    \[ [@ref-7], [@ref-18], [@ref-23], [@ref-33], [@ref-41], [@ref-54], [@ref-61], [@ref-73], [@ref-85], [@ref-87], [@ref-102]\]   2998          385 (13)                 (2--95) \[ [@ref-85]\] - \[ [@ref-61]\]

     **Bradycardia (mild and severe)** [‡](#fn7){ref-type="other"}   \[ [@ref-23], [@ref-36], [@ref-54], [@ref-61], [@ref-65], [@ref-85], [@ref-90], [@ref-91], [@ref-115], [@ref-117]\]            882           94 (11)                  (0--49) \[ [@ref-36]\] - \[ [@ref-61]\]

     **Decrease in heart rate** [‡](#fn7){ref-type="other"}          \[ [@ref-41], [@ref-54], [@ref-61], [@ref-80]\]                                                                                193           152 (79)                 (11--94) \[ [@ref-80]\] - \[ [@ref-41]\]

     **Tachycardia** [‡](#fn7){ref-type="other"}                     \[ [@ref-23], [@ref-27], [@ref-36]\]                                                                                           565           13 (2)                   (0--6) \[ [@ref-36]\] - \[ [@ref-23]\]

     **Ventricular extrasystoles** [‡](#fn7){ref-type="other"}       \[ [@ref-73]\]                                                                                                                 22            11 (50)                  

     **Cardiac event, unspecified** [‡](#fn7){ref-type="other"}      \[ [@ref-26], [@ref-86]\]                                                                                                      165           18 (11)                  (5--12) \[ [@ref-26]\] - \[ [@ref-86]\]

     **Asystole** [¶](#fn9){ref-type="other"}                        \[ [@ref-91], [@ref-100]\]                                                                                                     45            3 (7)                    (3--20) \[ [@ref-100]\] - \[ [@ref-91]\]

     **Left cardiac insufficiency**                                  \[ [@ref-85]\]                                                                                                                 194           1 (1)                    

     **Chest discomfort/tightness** [‡](#fn7){ref-type="other"}      \[ [@ref-18], [@ref-27], [@ref-54], [@ref-73], [@ref-87], [@ref-91], [@ref-115]\]                                              901           22 (2)                   (1--10) \[ [@ref-27]\] - \[ [@ref-54]\]

  ***Respiratory***                                                                                                                                                                                                                        

     **Unspecified respiratory**\                                    \[ [@ref-26], [@ref-86]\]                                                                                                      165           43 (26)                  (21--62) \[ [@ref-86]\] - \[ [@ref-26]\]
  **symptoms** [‡](#fn7){ref-type="other"}                                                                                                                                                                                                 

     **Dyspnea** ^[d](#fn9){ref-type="other"}^                       \[ [@ref-18], [@ref-27], [@ref-54], [@ref-66], [@ref-85]\]                                                                     2748          26 (1)                   (0--10) \[ [@ref-66]\] - \[ [@ref-54]\]

     **Cough**                                                       \[ [@ref-85], [@ref-101]\]                                                                                                     373           52 (14)                  (5--22) \[ [@ref-101]\] \[ [@ref-85]\]

     **Lung edema** [‡](#fn7){ref-type="other"}                      \[ [@ref-59], [@ref-85]\]                                                                                                      241           3 (1)                    (1--2) \[ [@ref-85]\] - \[ [@ref-59]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Incidences of the adverse reactions have been calculated for all the individual studies. (min%--max%) are the lowest and highest observed incidence of an adverse reaction.

‡ DMSO was administered intravenously in all studies.

§ DMSO was administered intravenously in all studies. Horacek *et al.* \[ [@ref-102]\] measured 42 patients with an increase in systolic blood pressure, and 31 patients with an increase in diastolic blood pressure. This was counted as 73 cases of hypertension.

¶ In both studies, asystole occurred because of DMSO effect on the trigeminal nerve and activation of the trigeminal cardiac reflex. d) in one study DMSO was administered transdermally

###### Cardiovascular and respiratory adverse reactions observed per number of treatments.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse reaction                                                    Studies                                Total number of\   Adverse reactions\   (min%--max%) [†](#fn10){ref-type="other"}
                                                                                                             treatments         observed, n (%)      
  ------------------------------------------------------------------- -------------------------------------- ------------------ -------------------- -------------------------------------------
  ***Cardiac***                                                                                                                                      

     **Hypotension** [‡](#fn11){ref-type="other"}                     \[ [@ref-40], [@ref-51], [@ref-68]\]   323                10 (3)               (2--14) \[ [@ref-68]\] - \[ [@ref-40]\]

     **Hypertension** [‡](#fn11){ref-type="other"}                    \[ [@ref-25], [@ref-51], [@ref-68]\]   425                60 (14)              (3--21) \[ [@ref-25]\] - \[ [@ref-68]\]

     **Bradycardia (mild and severe)** [‡](#fn11){ref-type="other"}   \[ [@ref-51]\]                         54                 4 (7)                

     **Decrease in heartrate** [‡](#fn11){ref-type="other"}           \[ [@ref-39]\]                         32                 30 (94)              

     **Tachycardia** [‡](#fn11){ref-type="other"}                     \[ [@ref-51]\]                         54                 4 (7)                

     **Cardiac event, unspecified** [‡](#fn11){ref-type="other"}      \[ [@ref-74]\]                         1269               35 (3)               

     **Chest discomfort/tightness** [‡](#fn11){ref-type="other"}      \[ [@ref-25], [@ref-68], [@ref-74]\]   1640               83 (5)               (0--6) \[ [@ref-68]\] - \[ [@ref-74]\]

  ***Respiratory***                                                                                                                                  

     **Dyspnea**                                                      \[ [@ref-25], [@ref-68]\]              371                3 (1)                (0--2) \[ [@ref-68]\] - \[ [@ref-25]\]

     **Shortness of breath** [‡](#fn11){ref-type="other"}             \[ [@ref-74]\]                         1269               40 (3)               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Incidences of the adverse reactions have been calculated for all the individual studies. (%, min-max) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.

‡ DMSO was administered intravenously.

Bradycardia was defined as a heart rate less than 60 beats per minute ^[@ref-41],\ [@ref-61]^ and was often transient ^[@ref-23],\ [@ref-61],\ [@ref-90],\ [@ref-115]^, but cases where atropine was needed are described ^[@ref-49],\ [@ref-96]^. A lowered heart rate not enough to be considered bradycardia was observed in four studies ^[@ref-39],\ [@ref-41],\ [@ref-54],\ [@ref-61]^.

In some studies, hypertension did not require intervention ^[@ref-61],\ [@ref-102]^, but cases where medication was needed to control the hypertension, or where treatment was stopped due to hypertension, are described ^[@ref-41],\ [@ref-54],\ [@ref-85]^. Hypotension was also described as transient most of the time ^[@ref-18],\ [@ref-23],\ [@ref-68],\ [@ref-87],\ [@ref-104]^, with some cases needing intervention ^[@ref-40],\ [@ref-51],\ [@ref-54]^.

One study reported 11 cases of transient extrasystoles in 22 patients receiving cryopreserved autologous blood stem cells, monitored with Holter during infusion ^[@ref-73]^. There were two studies reporting cases of asystole during embolization of dural arteriovenous fistulas with a substance called Onyx, a non-adhesive liquid embolic agent dissolved in DMSO ^[@ref-91],\ [@ref-100]^.

Dyspnea was reported in seven studies ^[@ref-18],\ [@ref-25],\ [@ref-27],\ [@ref-54],\ [@ref-66],\ [@ref-68],\ [@ref-85]^. A single study reported eight patients with transient shock after stem cell transfusion ^[@ref-51]^. Some of these patients developed loss of consciousness and cyanosis but recovered promptly and had no need for additional therapy, whereas the rest of the patients developed severe hypotension or transient dyspnea, which was described as the reason for the transient shock. Further description of the condition was not provided.

Several of the studies found a correlation between the dose of DMSO used and the incidence of cardiovascular adverse reactions ^[@ref-41],\ [@ref-67],\ [@ref-71],\ [@ref-75],\ [@ref-78],\ [@ref-85],\ [@ref-86],\ [@ref-93],\ [@ref-101],\ [@ref-115]^.

Dermatological reactions
------------------------

Dermatological side effects are common when DMSO is administered transdermally. Skin reactions or allergic reactions were reported in 58 studies. DMSO was applied transdermally in 43 studies ^[@ref-2],\ [@ref-4],\ [@ref-6],\ [@ref-17],\ [@ref-19]--\ [@ref-22],\ [@ref-24],\ [@ref-28]--\ [@ref-32],\ [@ref-37],\ [@ref-44],\ [@ref-45],\ [@ref-52],\ [@ref-55],\ [@ref-57],\ [@ref-63],\ [@ref-64],\ [@ref-66],\ [@ref-67],\ [@ref-69],\ [@ref-72],\ [@ref-75],\ [@ref-76],\ [@ref-78],\ [@ref-79],\ [@ref-82],\ [@ref-83],\ [@ref-88],\ [@ref-89],\ [@ref-93],\ [@ref-95],\ [@ref-96],\ [@ref-106],\ [@ref-108],\ [@ref-109],\ [@ref-111]--\ [@ref-113]^, intravenously in 14 studies ^[@ref-25],\ [@ref-40],\ [@ref-41],\ [@ref-51],\ [@ref-59],\ [@ref-73],\ [@ref-74],\ [@ref-77],\ [@ref-85],\ [@ref-86],\ [@ref-92],\ [@ref-98],\ [@ref-101],\ [@ref-110]^ and intraarticular in one ^[@ref-103]^ ( [Table 5](#T5){ref-type="table"}).

###### Dermatological and allergic adverse reactions observed per number of patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse reactions                                                                  Studies                                                                                                                                                                     Total\        Patients\          (%, min-max) [†](#fn12){ref-type="other"}
                                                                                                                                                                                                                                                                 patients, n   with adverse\      
                                                                                                                                                                                                                                                                               reactions, n (%)   
  ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------------ -----------------------------------------------------
  ***Skin reactions***                                                                                                                                                                                                                                                                            

     **Erythema** [‡](#fn13){ref-type="other"}                                       \[ [@ref-19], [@ref-32], [@ref-64], [@ref-66], [@ref-82], [@ref-95]\]                                                                                                       2352          201 (9)            (3--95) \[ [@ref-95]\] - \[ [@ref-82]\]

     **Itching/Pruritus** [‡](#fn13){ref-type="other"}                               \[ [@ref-6], [@ref-55], [@ref-57], [@ref-64], [@ref-66], [@ref-72], [@ref-82], [@ref-93]\]                                                                                  3421          215 (6)            (0--70) \[ [@ref-55]\] - \[ [@ref-82]\]

     **Urticaria** [‡](#fn13){ref-type="other"}                                      \[ [@ref-24], [@ref-31], [@ref-83]\]                                                                                                                                        58            9 (16)             (4--59) \[ [@ref-24]\] - \[ [@ref-83]\]

     **Rash**                                                                        \[ [@ref-29], [@ref-30], [@ref-55], [@ref-57], [@ref-64], [@ref-93], [@ref-101], [@ref-111]\]                                                                               2682          121 (5)            (1--40) \[ [@ref-30]\] - \[ [@ref-93]\]

     **Paresthesia/burning or**\                                                     \[ [@ref-17], [@ref-21], [@ref-24], [@ref-28], [@ref-30], [@ref-44], [@ref-45], [@ref-55], [@ref-57], [@ref-67], [@ref-69], [@ref-79], [@ref-91], [@ref-93], [@ref-106]\]   2141          335 (16)           (0--100) \[ [@ref-30]\] - \[ [@ref-45]\]
  **stinging sensation** [§](#fn14){ref-type="other"} [‡](#fn13){ref-type="other"}                                                                                                                                                                                                                

     **Scaling of skin/desquamation/**\                                              \[ [@ref-22], [@ref-29], [@ref-30], [@ref-37], [@ref-52], [@ref-55], [@ref-57], [@ref-64], [@ref-66], [@ref-69], [@ref-75], [@ref-82], [@ref-88], [@ref-89], [@ref-106]\]   4739          731 (15)           (1--96) \[ [@ref-66]\] - \[ [@ref-52]\]
  **dry skin/local irritant** [‡](#fn13){ref-type="other"}                                                                                                                                                                                                                                        

     **Blistering** [‡](#fn13){ref-type="other"}                                     \[ [@ref-31], [@ref-32], [@ref-66], [@ref-69], [@ref-93], [@ref-112]\]                                                                                                      2038          79 (4)             (3--20) \[ [@ref-66]\] - \[ [@ref-112]\]

     **Roughness and/or thickening**\                                                \[ [@ref-66], [@ref-82], [@ref-93]\]                                                                                                                                        1986          191 (10)           (6--10) \[ [@ref-93]\] - \[ [@ref-82]\]
  **of skin** [‡](#fn13){ref-type="other"}                                                                                                                                                                                                                                                        

     **Bullous dermatitis/dermatitis**\                                              \[ [@ref-20], [@ref-29], [@ref-64]\]                                                                                                                                        1116          79 (7)             (1--9) \[ [@ref-64]\] - \[ [@ref-29]\]
  **with vesicles** [‡](#fn13){ref-type="other"}                                                                                                                                                                                                                                                  

     **Contact dermatitis** [‡](#fn13){ref-type="other"}                             \[ [@ref-6], [@ref-20], [@ref-28]-- [@ref-30], [@ref-64], [@ref-111]\]                                                                                                      2587          161 (6)            (1--13) \[ [@ref-28]\] - \[ [@ref-29]\]

     **Skin reaction, unspecified** [‡](#fn13){ref-type="other"}                     \[ [@ref-2], [@ref-78], [@ref-96], [@ref-113]\]                                                                                                                             457           159 (35)           (4--48) \[ [@ref-96]\] - \[ [@ref-113]\]

     **Increase in skin pigmentation** [‡](#fn13){ref-type="other"}                  \[ [@ref-6]\]                                                                                                                                                               548           28 (5)             

     **Peripheral edema** [‡](#fn13){ref-type="other"}                               \[ [@ref-45], [@ref-55], [@ref-66], [@ref-109]\]                                                                                                                            2291          22 (0)             (1--14) \[ [@ref-66]\] - \[ [@ref-109]\]

  ***Allergic reactions***                                                           \[ [@ref-37], [@ref-44], [@ref-59], [@ref-86], [@ref-98], [@ref-110]\]                                                                                                      309           75 (24)            (3--55) \[ [@ref-44], [@ref-110]\] - \[ [@ref-86]\]

    Intravenous administration                                                       \[ [@ref-59], [@ref-86], [@ref-98], [@ref-110]\]                                                                                                                            229           66 (29)            (2--55) \[ [@ref-59]\] - \[ [@ref-86]\]

    Transdermal application                                                          \[ [@ref-37], [@ref-44]\]                                                                                                                                                   86            9 (10)             (3--19) \[ [@ref-44]\] - \[ [@ref-37]\]

    Flushing [¶](#fn15){ref-type="other"}                                            \[ [@ref-41], [@ref-54], [@ref-73]\]                                                                                                                                        292           34 (12)            (2--9) \[ [@ref-54]\] - \[ [@ref-73]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Incidences of the adverse reactions have been calculated for all the individual studies. (min%--max%) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.

‡ Transdermal application only.

§ One study administered DMSO through intraarticular injection \[ [@ref-38]\].

¶ DMSO was administered intravenously in all studies.

The most common skin reaction was a local burning sensation reported in 13 studies ^[@ref-17],\ [@ref-21],\ [@ref-24],\ [@ref-28],\ [@ref-30],\ [@ref-45],\ [@ref-55],\ [@ref-57],\ [@ref-67],\ [@ref-69],\ [@ref-79],\ [@ref-93],\ [@ref-106]^. In one study, all participants experienced this burning sensation ^[@ref-45]^. In the same study, four participants experienced a transient peripheral edema associated with itching and erythema ^[@ref-45]^. A single study described a burning sensation in four of 669 patients when DMSO was given as a local injection ^[@ref-92]^; another study described burning in two out of 17 patients when DMSO was injected intraarticularly ^[@ref-103]^.

Most skin reactions were transient, only lasting minutes ^[@ref-17],\ [@ref-24],\ [@ref-32],\ [@ref-67],\ [@ref-72]^, but some studies reported cases described as serious, causing discontinuation of treatment ^[@ref-2],\ [@ref-6],\ [@ref-52],\ [@ref-63],\ [@ref-78],\ [@ref-96]^. There were two studies describing that skin reactions to DMSO would disappear after days of continuous treatment ^[@ref-45],\ [@ref-83]^. Another study reported that 1 of 18 patients treated for psoriasis with DMSO was hospitalized due to exfoliative erythroderma ^[@ref-63]^. In another study, two patients, diagnosed with dermographia developed prominent areas of weals after DMSO application ^[@ref-95]^.

Acute allergic reactions due to use of DMSO were reported in six studies ^[@ref-37],\ [@ref-44],\ [@ref-59],\ [@ref-86],\ [@ref-98],\ [@ref-110]^. One study reported that 63 of 144 patients experienced allergic reactions, which was not described as serious adverse events (bronchospasms, facial flushing, rash) ^[@ref-86]^. In two other studies, acute allergic reactions were characterized as serious adverse events ^[@ref-59],\ [@ref-110]^.

Flushing was regarded as an allergic reaction in this review and was only reported when DMSO was administered intravenously ^[@ref-25],\ [@ref-40],\ [@ref-41],\ [@ref-51],\ [@ref-54],\ [@ref-73],\ [@ref-74]^. A total of four studies, not depicted in [Table 5](#T5){ref-type="table"}, reported 204 cases of flushing during 1439 stem cell infusions ^[@ref-25],\ [@ref-40],\ [@ref-51],\ [@ref-74]^. Several studies observed a relationship between the dose of DMSO and the occurrence of adverse reactions ^[@ref-67],\ [@ref-75],\ [@ref-78],\ [@ref-83],\ [@ref-88],\ [@ref-93]^.

Neurological reactions
----------------------

Headache is the most common neurological adverse reaction reported. In one study, headache was the reason for withdrawal of 2 out of 21 patients being treated with DMSO ^[@ref-116]^.

Three studies using DMSO as a cryoprotectant in stem cell transfusions described seizures after administration ^[@ref-18],\ [@ref-36],\ [@ref-47]^. Severe encephalopathy was observed in one patient ^[@ref-99]^, and transient cranial nerve III and IV palsy was observed in one patient after Onyx embolization ^[@ref-34]^. One study described neurological symptoms occurring during and after transfusion, but they did not define neurological symptoms in detail ^[@ref-86]^.

Urogenital reactions
--------------------

Few urogenital reactions were described ( [Table 6](#T6){ref-type="table"} and [Table 7](#T7){ref-type="table"}). Hemoglobinuria was described as an adverse reaction seen after transfusion of stem cell products ^[@ref-39],\ [@ref-51],\ [@ref-56],\ [@ref-73]^. However, hemoglobinuria is often attributed to erythrocyte debris in the transplant material and has thus not been interpreted as being caused by DMSO ^[@ref-39],\ [@ref-73]^. The other urogenital reactions ( [Table 6](#T6){ref-type="table"} and [Table 7](#T7){ref-type="table"}) all occurred after DMSO instillation in the bladder ^[@ref-38],\ [@ref-49],\ [@ref-97]^.

###### Neurological and urogenital adverse reactions observed per number of patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse reaction                       Studies                                                                                                                                                                                            Total\        Patients\          (min%--max%) [†](#fn16){ref-type="other"}
                                                                                                                                                                                                                                            patients, n   with adverse\      
                                                                                                                                                                                                                                                          reactions, n (%)   
  -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------------ -------------------------------------------
  ***Neurological***                                                                                                                                                                                                                                                         

     **Headache**                        \[ [@ref-2], [@ref-18], [@ref-29], [@ref-33], [@ref-38], [@ref-41], [@ref-55], [@ref-59], [@ref-70], [@ref-71], [@ref-81], [@ref-84], [@ref-85], [@ref-98], [@ref-101], [@ref-104], [@ref-116]\]   2516          150 (6)            (1--50) \[ [@ref-101]\] - \[ [@ref-70]\]

    Intravenous administration           \[ [@ref-18], [@ref-33], [@ref-41], [@ref-59], [@ref-70], [@ref-71], [@ref-81], [@ref-85], [@ref-98], [@ref-101], [@ref-104]\]                                                                     1271          42 (3)             (1--50) \[ [@ref-101]\] - \[ [@ref-70]\]

    Transdermal application              \[ [@ref-2], [@ref-29], [@ref-55]\]                                                                                                                                                                1197          102 (8)            (5--35) \[ [@ref-55]\] - \[ [@ref-2]\]

    Intravesical administration          \[ [@ref-38]\]                                                                                                                                                                                     20            1 (5)              

    Rectal administration                \[ [@ref-116]\]                                                                                                                                                                                    21            3 (14)             

    \>1 administration route             \[ [@ref-84]\]                                                                                                                                                                                     7             2 (29)             

     **Seizures**                        \[ [@ref-18], [@ref-36], [@ref-47]\]                                                                                                                                                               301           2 (1)              (0--2) \[ [@ref-18]\] - \[ [@ref-47]\]

     **Neurological symptoms,**\         \[ [@ref-86]\]                                                                                                                                                                                     144           5 (3)              
  **unspecified**                                                                                                                                                                                                                                                            

     **Transient CN III and IV palsy**   \[ [@ref-34]\]                                                                                                                                                                                     12            1 (8)              

     **Severe encephalopathy**           \[ [@ref-99]\]                                                                                                                                                                                     124           1 (1)              

  ***Urogenital***                                                                                                                                                                                                                                                           

     **Pelvic discomfort/pain/**\        \[ [@ref-38], [@ref-49], [@ref-97]\]                                                                                                                                                               107           10 (9)             (6--30) \[ [@ref-49]\] - \[ [@ref-38]\]
  **irritation**                                                                                                                                                                                                                                                             

     **Dysuria/strangury**               \[ [@ref-49]\]                                                                                                                                                                                     36            6 (17)             

     **Renal and urinary disorder**      \[ [@ref-49]\]                                                                                                                                                                                     36            8 (22)             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Incidences of the adverse reactions have been calculated for all the individual studies. (min%--max%) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.

###### Neurological and urogenital adverse reactions observed per number of treatments.

  -----------------------------------------------------------------------------------------------------------------------------------------
  Adverse reaction             Studies                     Total\          Adverse reactions\   (min%--max%) [†](#fn17){ref-type="other"}
                                                           treatments, n   observed, n (%)      
  ---------------------------- --------------------------- --------------- -------------------- -------------------------------------------
  ***Neurological***                                                                            

     **Headache**              \[ [@ref-39], [@ref-51]\]   86              40 (47)              (6 - 73) \[ [@ref-39]\] - \[ [@ref-51]\]

  ***Urogenital***                                                                              

     **Urethral irritation**   \[ [@ref-73]\]              151             110 (73)             
  -----------------------------------------------------------------------------------------------------------------------------------------

^†^Incidences of the adverse reactions have been calculated for all the individual studies. (%, min-max) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.

Other reactions
---------------

Only one study in this review administered DMSO as eye-drops ^[@ref-114]^. In this study, two patients experienced severe conjunctival hyperemia due to allergic reactions, and 25% of patients experienced a stinging sensation when eye-drops were applied ^[@ref-114]^. Other studies performed eye examinations to determine whether DMSO caused changes in the lens; however, no such cases were observed ^[@ref-2],\ [@ref-45]^.

Hyponatremia occurred in six patients after they received large doses of DMSO as treatment for cranial hypertension ^[@ref-62]^. This adverse reaction was not reported in other studies ( [Table 8](#T8){ref-type="table"}).

###### Other adverse reactions observed per number of patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse\           Studies                                                                             Total\        Patients with\    (min%--max%) [†](#fn18){ref-type="other"}
  reaction                                                                                               patients, n   reaction, n (%)   
  ------------------ ----------------------------------------------------------------------------------- ------------- ----------------- -------------------------------------------
  **Fever**          \[ [@ref-27], [@ref-71], [@ref-73], [@ref-77], [@ref-101]\]                         547           44 (8)            (2--19) \[ [@ref-27]\] - \[ [@ref-77]\]

  **Chills**         \[ [@ref-27], [@ref-33], [@ref-70], [@ref-71], [@ref-81], [@ref-85], [@ref-101]\]   852           60 (7)            (1--31) \[ [@ref-101]\] - \[ [@ref-71]\]

  **Dizziness**      \[ [@ref-2], [@ref-46], [@ref-55], [@ref-85], [@ref-101]\]                          885           18 (2)            (1--15) \[ [@ref-55]\] - \[ [@ref-2]\]

  **Weakness**       \[ [@ref-33], [@ref-45], [@ref-46]\]                                                293           19 (6)            (1--29) \[ [@ref-46]\] - \[ [@ref-45]\]

  **Sedation**       \[ [@ref-2]\]                                                                       78            34 (44)           

  **Hyponatremia**   \[ [@ref-62]\]                                                                      6             6 (100)           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Incidences of the adverse reactions have been calculated for all the individual studies. (%, min-max) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.

Very few cases of serious adverse reactions associated with DMSO have been described ^[@ref-18],\ [@ref-36],\ [@ref-51],\ [@ref-59]^.

Overall, most studies administered DMSO intravenously or transdermally ( [Table 9](#T9){ref-type="table"})

###### Way of administration of DMSO in included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Administration        Number\      References
                        of studies   
  --------------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Intravenous**       49           \[ [@ref-7], [@ref-16], [@ref-18], [@ref-23], [@ref-25], [@ref-26], [@ref-33], [@ref-34], [@ref-36], [@ref-39]-- [@ref-41], [@ref-46]-- [@ref-48], [@ref-51], [@ref-53], [@ref-54], [@ref-56], [@ref-59], [@ref-61], [@ref-62], [@ref-65], [@ref-68], [@ref-70]-- [@ref-74],\
                                     [@ref-77], [@ref-80], [@ref-81], [@ref-84]-- [@ref-87], [@ref-90], [@ref-91], [@ref-94], [@ref-98]-- [@ref-102], [@ref-104], [@ref-110], [@ref-115], [@ref-117], [@ref-118]\]

  **Transdermal**       48           \[ [@ref-2], [@ref-4], [@ref-6], [@ref-17], [@ref-19]-- [@ref-22], [@ref-24], [@ref-28]-- [@ref-32], [@ref-37], [@ref-42], [@ref-44], [@ref-45], [@ref-50], [@ref-52], [@ref-55], [@ref-57], [@ref-58], [@ref-63], [@ref-64], [@ref-66], [@ref-67], [@ref-69], [@ref-72], [@ref-75], [@ref-76], [@ref-78], [@ref-79],\
                                     [@ref-82]-- [@ref-84], [@ref-88], [@ref-89], [@ref-93], [@ref-95], [@ref-96], [@ref-106]-- [@ref-109], [@ref-111]-- [@ref-113]\]

  **Intravesical**      7            \[ [@ref-8], [@ref-35], [@ref-38], [@ref-43], [@ref-49], [@ref-97], [@ref-105]\]

  **Oral**              2            \[ [@ref-9], [@ref-60]\]

  **Eye-drops**         1            \[ [@ref-114]\]

  **Local injection**   1            \[ [@ref-92]\]

  **Intra-articular**   1            \[ [@ref-103]\]

  **Rectal**            1            \[ [@ref-116]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Risk of bias within studies
---------------------------

In this review, we included 76 cohort studies, of which 64 were prospective ^[@ref-2],\ [@ref-4],\ [@ref-6],\ [@ref-7],\ [@ref-20],\ [@ref-22],\ [@ref-24]--\ [@ref-27],\ [@ref-29],\ [@ref-31],\ [@ref-32],\ [@ref-34]--\ [@ref-38],\ [@ref-40]--\ [@ref-45],\ [@ref-48],\ [@ref-50]--\ [@ref-54],\ [@ref-56],\ [@ref-58],\ [@ref-60],\ [@ref-63],\ [@ref-65],\ [@ref-66],\ [@ref-68]--\ [@ref-70],\ [@ref-72],\ [@ref-73],\ [@ref-77],\ [@ref-80],\ [@ref-81],\ [@ref-83],\ [@ref-85],\ [@ref-88],\ [@ref-90],\ [@ref-92],\ [@ref-94],\ [@ref-97],\ [@ref-98],\ [@ref-101]--\ [@ref-104],\ [@ref-107],\ [@ref-108],\ [@ref-110],\ [@ref-112],\ [@ref-115],\ [@ref-117],\ [@ref-118]^ and 13 were retrospective ^[@ref-9],\ [@ref-18],\ [@ref-23],\ [@ref-39],\ [@ref-46],\ [@ref-47],\ [@ref-61],\ [@ref-71],\ [@ref-74],\ [@ref-86],\ [@ref-87],\ [@ref-100],\ [@ref-105]^. Bias was assessed using The Newcastle-Ottawa-Scale ^[@ref-14]^. Using this scale, studies were given zero to nine stars. A high number of stars equals low risk of bias and vice versa. The studies in this review had a median value of 5 stars, with a range of 2--8. No studies received the highest possible value of nine stars. Very few studies had a comparison group that did not receive DMSO, and often the occurrence of adverse reactions was poorly described. There were 24 randomized controlled trials ( [Figure 2](#f2){ref-type="fig"}). Many studies received an unclear risk of bias because often it was vaguely described how adverse reactions were reported.

![Risk of bias in randomized controlled trials.](f1000research-7-22126-g0001){#f2}

Overall, there was a high risk of bias when assessing the description of adverse reactions. Some studies were not assessed for bias due to being case-reports, preliminary trials, or because they included more than one study design ^[@ref-17],\ [@ref-19],\ [@ref-28],\ [@ref-62],\ [@ref-84],\ [@ref-91],\ [@ref-99],\ [@ref-109],\ [@ref-111],\ [@ref-113]^.

Discussion
==========

Gastrointestinal and dermatological adverse reactions were the most commonly reported in the included studies. Cardiac adverse reactions only occurred when DMSO was administered intravenously, whereas dermatological reactions mostly occurred when DMSO was administered on the skin. Serious neurological and cardiac reactions were rare and only described in few studies. There seems to be a dose-response relationship between DMSO and adverse reactions with no or mild reactions in low doses.

Many studies on the use of DMSO have been performed in Russia. These studies have not been readily accessible to the global community due to the language barrier. In this review, we have included not only studies dating back almost 50 years, but also articles written in Russian, which is an important strength of the review. This study has several limitations: 1) Some studies used the NCI-CTC (National Cancer Institute's Common Terminology Criteria for adverse events), but often no scale was used, and the occurrence of adverse reactions were poorly reported. 2) It was difficult to make conclusions on the frequency of a specific adverse reaction, because the exact number of patients experiencing a reaction was often not stated. 3) Several studies using DMSO as a cryoprotectant concluded that other factors affected the occurrence of adverse reactions ^[@ref-7],\ [@ref-85],\ [@ref-86]^. One study prospectively looked at the adverse reactions observed in relation to autologous transplantation in 64 European Blood and Marrow Transplant Group centers ^[@ref-7]^. They had difficulties isolating the effects of DMSO from confounding factors such as cell breakdown products and conditioning chemotherapy. Factors such as age, gender, volume transfused, granulocyte concentration, clumping of transplant material, and amount of red blood cells played a role in the occurrence of adverse reactions ^[@ref-61],\ [@ref-86],\ [@ref-120]--\ [@ref-122]^. Another study believed that acute volume expansion, electrolyte imbalance and vagal responses to the coldness of the freshly thawed infusate were more likely reasons for cardiac arrhythmias during stem cell transfusions than the DMSO infused ^[@ref-123]^. This differs from other studies, which found a clear connection between dose of DMSO and occurrence of cardiac adverse reactions ^[@ref-41],\ [@ref-67],\ [@ref-71],\ [@ref-75],\ [@ref-78],\ [@ref-85],\ [@ref-86],\ [@ref-93],\ [@ref-101],\ [@ref-115]^. Therefore, it is possible that some adverse reactions are more or less common than found in this review. The rarer side effects are often reported in case reports, which often did not meet the eligibility criteria in this review. However, we have included several larger studies in this review, and they found a very small occurrence of serious adverse events ^[@ref-7],\ [@ref-55],\ [@ref-66],\ [@ref-74]^.

In conclusion, adverse reactions due to DMSO are often mild and transient and do not qualify as serious adverse events. Cardiovascular and respiratory adverse reactions occur mostly when DMSO is administered intravenously, whereas dermatological reactions have a higher incidence when DMSO is administered transdermally. An important finding is that the occurrence of adverse reactions seems to be related to the dose of DMSO, and it therefore seems safe to continue the use of DMSO in small doses.

Data availability
=================

All data underlying the results are available as part of the article and no additional source data are required.

Supplementary material {#SM1}
======================

**Supplementary File 1. Completed PRISMA harms checklist.**

Click here for additional data file.
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Dear Igho J. Onakpoya,

Thank your for reviewing our manuscript "Adverse reactions of dimethyl sulfoxide in humans: a systematic review". Your comments were very helpful and we appreciate the effort you put in to reviewing our manuscript. We have addressed the individual questions in the section below. We hope your find our replies satisfactory. Questions are written in *italic*and answers in plain.

*Q1:* *The term "possible adverse reactions" is incorrect. Suspected adverse reactions is more reasonable.*

A1: We have changed the paragraph in the introduction section to "suspected adverse reactions".

*Q2: If Russian articles were screened by only one author, how were discrepancies resolved in these cases? Specify which authors extracted the data, and whether this was done independently.*

A1: We have clarified in the manuscript how the screening process was performed *: "*Two authors (B.K.M. and D.Z.) independently screened title and abstract according to the eligibility criteria using www.covidence.org. Discrepancies were resolved by discussion. One author screened the full-text articles (B.K.M.). Russian articles were screened by an author fluent in Russian (M.H.). If M.H was in doubt regarding inclusion of a study the results were presented to B.K.M and then discussed until a mutual decision was made. After the screening process was finished, all included studies were imported to an Excel sheet (Microsoft Excel 2016). Data extraction was performed by two authors (M.H. extracted from the Russian articles and B.K.M. extracted from the rest) *."*

*Q3: The term "possibly due" is incorrect. There are 4 levels in describing associations between medicines and suspected adverse reactions. The authors should revise their terminology*.

A3: We have rewritten the paragraph so it now states: "Gastrointestinal adverse reactions were reported in 61 studies. Of these, 10 studies were randomized controlled trials. *"*

*Q4: You state "in some studies patients discontinued treatments due to halitosis"; however, you have provided references for 5 studies -- the report can be more precise*

A4: We have made our report more precise and it now states: "In five studies, patients discontinued treatment due to halitosis."

*Q5:* *How does "including Russian studies" strengthen the review? What about several other languages that have been omitted*?

A5: A Russian Chemist, Dr. Alexander Saytzeff, identified DMSO in 1866, however it was not used for medical use at the time ^[1](https://f1000research.com/articles/7-1746#ref-1)^ . But the fact that he was Russian might have been the reason why Russian scientists have made numerous studies using DMSO. We therefore thought it would be valuable to include Russian articles since many of these studies have never been translated, and therefore are not available to the international scientific society. Of course, we could have included many other languages, but we thought it most relevant to include Russian since we observed a large amount of articles in Russian during our initial examination of the subject.

*Q6:  You state that there seems to be a dose-response relationship and have drawn similar conclusions. However, at no point in the results do you report data to support this claim. You state that studies reported associations between dose and the occurrence of adverse reactions but fail to report the doses in question.*

A6: As mentioned in our study several studies described a dose-response relationship between the amount of DMSO and the occurrence of adverse reactions ( ^[26](https://f1000research.com/articles/7-1746#ref-26)^ ^,^ ^[33](https://f1000research.com/articles/7-1746#ref-33)^ ^,^ ^[41](https://f1000research.com/articles/7-1746#ref-41)^ ^,^ ^[53](https://f1000research.com/articles/7-1746#ref-53)^ ^,^ ^[67](https://f1000research.com/articles/7-1746#ref-67)^ ^,^ ^[71](https://f1000research.com/articles/7-1746#ref-71)^ ^,^ ^[73](https://f1000research.com/articles/7-1746#ref-73)^ ^,^ ^[75](https://f1000research.com/articles/7-1746#ref-75)^ ^,^ ^[78](https://f1000research.com/articles/7-1746#ref-78)^ ^,^ ^[83](https://f1000research.com/articles/7-1746#ref-83)^ ^,^ ^[85](https://f1000research.com/articles/7-1746#ref-85)^ ^,^ ^[86](https://f1000research.com/articles/7-1746#ref-86)^ ^,^ ^[93](https://f1000research.com/articles/7-1746#ref-93)^ ^,^ ^[101](https://f1000research.com/articles/7-1746#ref-101)^ ^,^ ^[115](https://f1000research.com/articles/7-1746#ref-115)^ ). However, since the doses of DMSO and the route of administration differ between the studies, we were not able to give an exact dose. We can only say that an association seems likely.

*Q7: Please enumerate the limitations of your review*

A7: We have enumerated the limitations listed in the discussion in the manuscript.
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Version 1

With well over 20,000 patients receiving DMSO based autologous transplants annually in Europe alone, this is a timely review of the toxic effects of this valuable agent. It has been performed in an appropriate and scholarly manner and brings added value by including the Russian literature not easily accessible to the average English-speaking reader.

However there are ways in which the review might be improved and give added value to the reader.

It is not easy to ascertain the number of patients receiving DMSO intravenously and those receiving it by other routes. A small table could clarify this. 

The side effect tables either as numbers of patients or numbers of treatments. If they cannot be presented as one combined set of data then some explanation of the two separate tables would be beneficial.

There seems to have been no attempt to quantify the dose of DMSO which patients have received or to characterize the severity of the reactions and relate these. Furthermore DMSO is usually a vehicle to facilitate giving the patient some other treatment e.g. a stem cell transplant or drug so the reasons for the use of DMSO are not clear. This also means there are side effects from the drug or treatment facilitated by the DMSO; is it possible to separate these effects in any way? Do the authors of the many papers selected for analysis recommend an upper limit to the amount of DMSO given or have a strategy for minimising the dose?

In their final paragraph the authors suggest that \"reactions due to DMSO are often mild and transient\". In their previous paragraph they admit that the case reports the less common and more severe side effects which did not meet the eligibility criteria of this review. However as long ago as 2005 it was possible to identify severe side effects in an appreciable number of cases (Windrum *et al.*, 2005 ^[@rep-ref-40223-1]^). Furthermore although they do not separate the factors responsible the authors of reference 7 record a SAE (Grades 3, 4 and 5) profile in excess of 3%. The authors should possibly be a little more circumspect in this paragraph particularly as they recommend the use of DMSO in (unspecified) small doses.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Madsen
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Herlev Hospital, Denmark
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Dear Curly Morris,

Thank for reviewing our manuscript: "Adverse reactions of dimethyl sulfoxide in humans: a systematic review". We appreciate the effort put into reviewing our manuscript, and we have tried our best to use your comments to improve our manuscript. We have addressed the individual questions in the section below. We hope your find our replies satisfactory. Questions are written in *italic*and answers in plain.

Q1: *It is not easy to ascertain the number of patients receiving DMSO intravenously and those receiving it by other routes. A small table could clarify this.*

A1: We have added a table (Table 9) to our manuscript describing the route of administration of DMSO.

Q2 & 3: *There seems to have been no attempt to quantify the dose of DMSO which patients have received or to characterize the severity of the reactions and relate these. Furthermore DMSO is usually a vehicle to facilitate giving the patient some other treatment e.g. a stem cell transplant or drug so the reasons for the use of DMSO are not clear. This also means there are side effects from the drug or treatment facilitated by the DMSO; is it possible to separate these effects in any way? Do the authors of the many papers selected for analysis recommend an upper limit to the amount of DMSO given or have a strategy for minimising the dose*?

*In their final paragraph the authors suggest that \"reactions due to DMSO are often mild and transient\". In their previous paragraph they admit that the case reports the less common and more severe side effects which did not meet the eligibility criteria of this review. However as long ago as 2005 it was possible to identify severe side effects in an appreciable number of cases (Windrum et al., 2005* [*^1^*](https://f1000research.com/articles/7-1746#rep-ref-40223-1) *). Furthermore although they do not separate the factors responsible the authors of reference 7 record a SAE (Grades 3, 4 and 5) profile in excess of 3%. The authors should possibly be a little more circumspect in this paragraph particularly as they recommend the use of DMSO in (unspecified) small doses*.

A2 & 3: DMSO is most often used as a vehicle in combination with other drugs. Therefore, it is not possible to separate completely the adverse reactions related to the use of DMSO and the adverse reactions related to other drugs, since adverse reactions such as nausea, vomiting, headache etc. are not specific for solely DMSO.

As described by the authors of reference 7 ^[7](https://f1000research.com/articles/7-1746#ref-7)^, it was difficult to isolate the effect of DMSO from side effects related to conditioning chemotherapy. The only adverse effect that can solely be attributed to DMSO is halitosis. Therefore, we could not conclude that DMSO was the cause of SAE's in reference 7 and have not included it in our study. Correctly, Windrum et al. [^1^](https://f1000research.com/articles/7-1746#rep-ref-40223-1) describes several adverse reactions which may be contributed to DMSO. However, the study does not describe the seriousness of the adverse reactions.

As described in our study, it is very possible that some events are underrepresented in our study, which is a limitation.

The upper limit was not described by any studies; on the other hand several studies evaluated different doses of DMSO and found that a lesser amount of DMSO created fewer adverse reactions ( [^61^](https://f1000research.com/articles/7-1746#ref-61) ^,^ [^86^](https://f1000research.com/articles/7-1746#ref-86) ^,^ [^120^](https://f1000research.com/articles/7-1746#ref-120) ^--^ [^122^](https://f1000research.com/articles/7-1746#ref-122).). Based on this observation, we feel confident that the use of small amounts of DMSO is recommendable, since DMSO works well as a vehicle. However, limiting the amount would always be desirable.

[^1]: No competing interests were disclosed.
